Sanne de Bruin

33 Transfusion practice in the non-bleeding critically ill; an international online survey – The TRACE Survey Figure 3. Platelet thresholds prophylactically without any planned invasive procedure and prophy- lactically prior to different procedures. Coagulopathy The majority (87%) of the respondents transfuse their patients with fresh frozen plasma, only 9.5% reported to use pooled plasma to correct coagulopathy. In non-bleeding patients who will not undergo an invasive procedure, an international normalized ratio (INR) > 3 is infrequently corrected. Only 7%would always correct a pro- longed INR (Figure 4A.). Vitamin K is the most commonly mentioned therapeutic agent to correct the INR in these patients (85%), followed by plasma (43%) and prothrombin complex (35%) (Figure 4B). More physicians would correct a INR >3 prior to an invasive procedure compared to patients who are not undergoing an invasive procedure (p <0.0001). Among the re- spondents, 31%would always correct a prolonged INR in this setting (Figure 4A). Also, prior to an invasive procedure, the majority (70%) most of the respondents would use vitamin K as a therapeutic option, followed by prothrombin complex (58%) and plasma (57%) (Figure 4C). To diagnose coagulopathy, INR/Prothrombin time (99%), activated partial thrombo- plastin time (APTT, 97%) and fibrinogen level (94%) are widely available tests in the 2